Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

E. O. Zhuravleva; N. Yu. Vel’ts; I. I. Snegireva; G. V. Kutekhova; R. N. Alyautdin

doi:10.1007/s11094-019-02059-z

Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

Authors: Zhuravleva E.O.¹, Vel’ts N.Y.¹, Snegireva I.I.¹, Kutekhova G.V.¹, Alyautdin R.N.¹
Affiliations:
1. Ministry of Health of the Russian Federation, Scientific Center for Expert Evaluation of Medicinal Products
Issue: Vol 53, No 7 (2019)
Pages: 668-671
Section: Discussion
URL: https://journals.rcsi.science/0091-150X/article/view/245937
DOI: https://doi.org/10.1007/s11094-019-02059-z
ID: 245937

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Second-generation antipsychotic substances, as compared with first-generation antipsychotics, are more effective in relation to psychotic symptoms and have significantly lower potential for developing extrapyramidal impairments such as parkinsonism and late dyskinesia. However, use of these agents is associated with significant weight gain in patients. Advances in the pharmacogenetics of antipsychotic-induced weight gain are analyzed here.